The Next Decade of Cell and Gene Therapies
May 7, 2025
Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems, and more; we ask experts about the future of advanced medicine.
5 min read
Cell & Gene
Coming Soon: the Power List
By Rob Coker
April 11, 2025
The 2025 Power List will be available soon!
2 min read
The Trump Effect on Cell and Gene: Science versus Shockwaves
April 1, 2025
Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track.
9 min read
Peter Marks Resigns from FDA
By Stephanie Vine
April 1, 2025
Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr. “Rather he wishes subservient confirmation of his misinformation and lies.”
3 min read
Building a Resilient CGT Workforce
By Daniel Palmacci
March 26, 2025
With competition for skilled employees in cell and gene therapy manufacturing high, companies need to ensure they are investing in training and mentorship.
3 min read
We Need to Talk About CRISPR
March 21, 2025
Neal Baer, editor of a collection of essays on CRISPR, says we must not overlook the dark side of the technology.
4 min read
Partnership Cuts Cost of CAR T Manufacturing
March 13, 2025
Manufacturing bottlenecks remain a key hurdle in CAR-T therapy. Can automation and digital integration change that? Trenchant and Autolomous explore the possibilities.
4 min read
Rethinking Osteoarthritis With Extracellular Vesicles
March 4, 2025
A single injection. Over a year of relief. No major side effects. Why researchers are excited about the potential of extracellular vesicles from umbilical cord-derived stem cells.
4 min read
RIDE: A New Approach to CRISPR Delivery
By Rob Coker
March 3, 2025
A new study reports targeted CRISPR delivery in retinal and neurological disease models – without viral vectors.
2 min read
The Risks and Rewards of Rare Diseases
By Stephanie Vine
February 28, 2025
Bluebird bio’s financial situation is a stark reminder of the challenges of developing advanced therapies for rare diseases.
4 min read